Eli Lilly and Company logo

Eli Lilly and Company (LLY)

Market Closed
20 Jun, 19:52
S/.
797. 00
-13
-1.6%
S/.
- Market Cap
104.2 P/E Ratio
5.2% Div Yield
0 Volume
6.64 Eps
S/. 810
Previous Close
Day Range
797 797
Year Range
718 946.5
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

LLY closed Friday lower at S/.797, a decrease of 1.6% from Thursday's close, completing a monthly decrease of -8.44% or S/.73.5. Over the past 12 months, LLY stock lost -5.29%.
LLY pays dividends to its shareholders, with the most recent payment made on Jun 10, 2025. The next estimated payment will be in In 2 months on Sep 10, 2025 for a total of S/.1.5.
The last earnings report, released on Apr 28, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.08%, based on the last three reports.
Eli Lilly and Company has completed 4 stock splits, with the recent split occurring on Oct 16, 1997.
The company's stock is traded on 15 different exchanges and in various currencies, with the primary listing on NYSE (USD).

LLY Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Eli Lilly: It Is A Bet On Human Longevity

Eli Lilly: It Is A Bet On Human Longevity

Eli Lilly's recent stock dip creates a compelling buying opportunity, with its valuation multiples falling to 2022 levels, despite explosive growth prospects and a deep, innovative product pipeline. Driven by blockbuster drugs Mounjaro and Zepbound, Lilly's revenue surged 45% YoY. Near-term PBM headwinds are manageable, given the drugs' superior clinical data and massive market demand. Beyond current successes, Lilly is innovating with a potential game-changing oral GLP-1 (orforglipron) and a visionary "one-and-done" gene therapy acquisition (Verve) targeting heart disease.

Seekingalpha | 1 hour ago
Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing

Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing

The latest trading day saw Eli Lilly (LLY) settling at $770.64, representing a +1.04% change from its previous close.

Zacks | 7 hours ago
Lilly declares third-quarter 2025 dividend

Lilly declares third-quarter 2025 dividend

INDIANAPOLIS , June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025.

Prnewswire | 14 hours ago

Eli Lilly and Company Dividends

Eli Lilly and Company logo
LLY In 1 month
Estimated
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 1 month ago
Paid
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 4 months ago
Paid
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 7 months ago
Paid
Quarterly
$1.3 Per Share
Eli Lilly and Company logo
LLY 10 months ago
Paid
Quarterly
$1.3 Per Share
Eli Lilly and Company logo
LLY 15 May 2024
Paid
Quarterly
$1.3 Per Share

Eli Lilly and Company Earnings

28 Apr 2025 Date
-
Cons. EPS
-
EPS
6 Feb 2025 Date
5.07
Cons. EPS
5.32
EPS
4 Feb 2025 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
1.47
Cons. EPS
1.18
EPS
8 Aug 2024 Date
2.6
Cons. EPS
3.92
EPS
Eli Lilly and Company logo
LLY In 1 month
Estimated
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 1 month ago
Paid
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 4 months ago
Paid
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 7 months ago
Paid
Quarterly
$1.3 Per Share
Eli Lilly and Company logo
LLY 10 months ago
Paid
Quarterly
$1.3 Per Share
Eli Lilly and Company logo
LLY 15 May 2024
Paid
Quarterly
$1.3 Per Share
28 Apr 2025 Date
-
Cons. EPS
-
EPS
6 Feb 2025 Date
5.07
Cons. EPS
5.32
EPS
4 Feb 2025 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
1.47
Cons. EPS
1.18
EPS
8 Aug 2024 Date
2.6
Cons. EPS
3.92
EPS

Eli Lilly and Company (LLY) FAQ

What is the stock price today?

The current price is S/.797.00.

On which exchange is it traded?

Eli Lilly and Company is listed on NYSE.

What is its stock symbol?

The ticker symbol is LLY.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Eli Lilly and Company ever had a stock split?

Eli Lilly and Company had 4 splits and the recent split was on Oct 16, 1997.

Eli Lilly and Company Profile

Drug Manufacturers - General Industry
Healthcare Sector
Mr. David A. Ricks CEO
BVL Exchange
US5324571083 ISIN
US Country
47,000 Employees
14 Feb 2025 Last Dividend
16 Oct 1997 Last Split
13 Jan 1978 IPO Date

Overview

Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.

Products and Services

  • Diabetes Care

    Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.

  • Oncology

    Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.

  • Immunology

    Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.

  • Digestive Diseases

    Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.

  • Neurological Disorders

    Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.

  • Other Therapeutic Areas

    The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.

Contact Information

Address: Lilly Corporate Center
Phone: 317 276 2000